HHS Vulnerability Disclosure, Help For salvage chemotherapy in the case of recurrent disease, we administered chemotherapeutic regimens including carboplatin with paclitaxel, gemcitabine, or liposomal doxorubicin. http://downloads.hindawi.com/journals/mbd/2010/207084.pdf, Kadoyama K, Kuwahara A, Yamamori M, Brown JB, Sakaeda T, Okuno Y. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. Characteristics of the 735 women receiving carboplatin-based chemotherapy. Clinical Practice Guidelines Prevention and Management of Dermatological Toxicities Related to Anticancer Agents, Adolescents and Young Adults Working Group, ESMO SIOG Cancer in the Elderly Working Group, Examination & Accreditation Working Group, Real World Data and Digital Health Working Group, Translational Research and Precision Medicine Working Group, ESMO-Magnitude of Clinical Benefit Scale Working Group, Press and Media Affairs Committee and Social Media Working Group, ESMO-MCBS Working Group: Open Call for New Extended Members, ESMO Co-Editors-in-Chief for ESMO Journals Open Call for Members, ESMO Clinical Research Observatory Task Force (ECRO), Notification of 2022 ESMO General Assembly Vote, EnLiST ESMO Adaptation of Line of Systemic Therapy, Cancer Patient Management During the COVID-19 Pandemic, Primary brain tumours in the COVID-19 era, Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era, Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era, Genitourinary cancers: Renal cell cancer in the COVID-19 era, Genitourinary cancers: Prostate cancer in the COVID-19 era, Gynaecological malignancies: Cervical cancer in the COVID-19 era, Gynaecological malignancies: Endometrial cancer in the COVID-19 era, Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Hodgkin lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Indolent B-NHL in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Multiple myeloma in the COVID-19 era, Head and neck cancers in the COVID-19 era, COVID-19 adapted recommendations Slide Sets, ESMO Courses on Medical Oncology for Medical Students, External Oncology Fellowship Opportunities, ESMO Resilience Task Force: Survey Series, ESMO-MORA Recertification Process and Requirements, ESMO Certificate of Professional Development, Professor of Cancer Research and Tony Charlton Chair, Monash University, Melbourne, Australia, Acknowledgements: Rationalizing Bureaucracy, Bibliography on Clinical Trial Procedures, ESMO Designated Centres of Integrated Oncology & Palliative Care, Palliative and Supportive Care Sessions at ESMO Congress 2022 Paris, Krebstherapie whrend der COVID-19-Pandemie, Traitement du Cancer au Cours de la Pandmie de COVID-19, Le Cure per il Cancro Durante la Pandemia da COVID-19, Cuidado del cncer durante la pandemia de COVID-19, Access to Cancer Medicines and Technologies, ESMOs Mission on Access to Cancer Medicines and Technologies, ESMO Public Policy Track and Special Sessions. In conclusion, in our present population of women with gynecological malignancies treated with platinum-based chemotherapy, 1 in 10 developed carboplatin-related hypersensitivity reactions. Clipboard, Search History, and several other advanced features are temporarily unavailable. J Oncol Pract. doi: 10.1159/000055363, Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., et al. Cancer. Markman, M. (2007). With a lower carboplatin infusion rate and pre-treatment with anti-allergy drugs, all of these patients were able to tolerate re-treatment with carboplatin, although 48 (78.7%) of these 61 patients developed hypersensitivity again despite the desensitization protocol. For more detailed information on the cookies we use, please check our Privacy Policy. This analysis includes 4772 pts. Efficacy and Adverse Events of Carboplatin Desensitisation Therapy for Gynaecological Cancer: A Retrospective Study. Most anticancer treatments carry a risk for infusion reactions which incidence may increase when different agents are administered concomitantly. (2010) described the use of cisplatin as an alternative to carboplatin. 2017 Nov 8;8:1472. doi: 10.3389/fimmu.2017.01472. Necessary cookies enable core functionality. Desensitization for hypersensitivity reactions to medications. We performed tests on occupational exposure (from 10 different health care surfaces) from three types of chemotherapy (Cyclophosphamide, Gemcitabine and Fluorouracil) from three different hospitals in Sweden. Guidelines | ESMO Women are more affected by drug allergy and up to 27% of women with ovarian and breast cancer develop carboplatin allergy after multiple cycles of treatment. To overcome drug allergy, desensitization has been developed, a novel approach which provides a unique opportunity to protect against anaphylaxis and to improve clinical outcomes. Cancer. (2003). Assess for pustules or blisters or erosions in addition to areas of "dusky erythema" which may feel painful to palpation. Educate. This study was approved by the Research Ethics Committee at the National Taiwan University Hospital (201706023RINC). Multivariate analyses of clinical parameters for carboplatin-related hypersensitivity reactions. J. Gynecol. (2005). Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies. 2022 May 20;12:879391. doi: 10.3389/fonc.2022.879391. However, severe carboplatin-related hypersensitivity symptoms can be fatal, as in one of our cases. Received: 23 July 2017; Accepted: 23 October 2017; Published: 06 November 2017. The ESMOClinical Practice Guidelines(CPGs) are intended to provide the user with a set of recommendations for the best standards of cancer care, based on the findings ofevidence-based medicine. Monitor. WHIPPANY, N.J., Sept. 1, 2017 /PRNewswire/ -- Bayer will present the latest research from across its growing oncology portfolio at the European Society for Medical Oncology (ESMO) 2017 Congress . Allergic and non-allergic ovarian cancer patients treated with carboplatin or carboplatin desensitization presented a similar life expectancy with a non significant advantage for the allergy desensitized patients. Epub 2017 Feb 24. Access all the congress resources: webcasts, news, press, posters, videos and much more. Tx-nave pts ORR was 90%. Prevention and Management of Dermatological Toxicities Related - ESMO Model of in vitro mouse mast cells activation and desensitization. 2022 Dec;11(12):1405-1418. doi: 10.1002/cpdd.1183. 20, 566573. This review provides insight into the current knowledge of drug allergy and anaphylaxis to cancer and chronic inflammatory diseases drugs, the mechanisms of drug desensitization and its applications to personalized medicine. Such reactions were scored according to the Common Terminology Criteria for Adverse Events version 4.03, with severity assessed as mild (grades 1 and 2) or severe (grades 3 and 4). 1; Mandac Smoljanovi, Inga 2. Successful carboplatin desensitization in patients with proven carboplatin allergy. Int. ESMO 2017 Congress Integrating science into oncology for a better patient outcome Start date 08 Sep 2017 End date 12 Sep 2017 Location Madrid, Spain In an era of deep understanding of the molecular biology underlying the development of cancer, it is crucial that researchers and clinicians exchange knowledge. Tyler T, Schultz A, Venturini A, Giuliano C, Bernareggi A, Spezia R, Voisin D, Stella V. Clin Pharmacol Drug Dev. PDF Hypersensitivity & Infusion Reaction Management - Stephenson Cancer Center Before J Exp Clin Cancer Res (2011) 30:93.10.1186/1756-9966-30-93 Gynecol. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel on patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. The yearly incidence of carboplatin-related hypersensitivity gradually increased from 0.88 in 2006 to 5.42% in 2013 (Table 1), in association with increased use of carboplatin. These recommendations aim to develop guidance to mitigate the negative effects of the COVID-19 pandemic on the diagnosis and treatment of cancer patients. 2023 Jan 23;11(2):252. doi: 10.3390/vaccines11020252. Check the latest publications and updates here to make sure you dont miss anything. 53, 121122. 66, 730. sharing sensitive information, make sure youre on a federal Monitor. doi: 10.1038/bjc.2013.389, Navo, M., Kunthur, A., Badell, M. L., Coffer, L. W. Clinical Practice Guidelines on Supportive Care - ESMO Educate. Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. ESMO is a Swiss-registered not-for-profit organisation. An official website of the United States government. 2017 Jun 20;18(6):1316. doi: 10.3390/ijms18061316. Platinum desensitization in patients with carboplatin hypersensitivity: a single-institution retrospective study. Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. Carboplatin hypersensitivity. Would you like email updates of new search results? Blood. official website and that any information you provide is encrypted Management of uncommon chemotherapy-induced emergencies. The site is secure. National Library of Medicine 17, 11411145. Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity. Br. Carriers of BRCA genes develop drug allergy after fewer exposures and can present with severe reactions, including anaphylaxis. Oncol. The cumulative incidence of carboplatin-related hypersensitivity reactions dramatically increased with >8 cycles or dose >3,500 mg. Patients feel psycho-social impact of chemo m | EurekAlert! Int J Mol Sci. (2006). *Correspondence: Wen-Fang Cheng, wenfangcheng@yahoo.com, Creative Commons Attribution License (CC BY). ESMO 2017 Congress | Madrid, Spain | Oncology Conferences 2022 Oct 18;12:994155. doi: 10.3389/fonc.2022.994155. Platinum-based combination chemotherapy is the recommended treatment for platinum-sensitive recurrent ovarian cancer (Parmar et al., 2003; Pfisterer et al., 2006; Pujade-Lauraine et al., 2010). 2019 Sep;60(9):2295-2298. doi: 10.1080/10428194.2019.1576871. This site needs JavaScript to work properly. The left side, Putative mechanism of protection against, Putative mechanism of protection against anaphylaxis during human desensitizations. Our findings also suggest that a history of drug or food allergies is a predictive factor for carboplatin-related hypersensitivity. ESMO is a Swiss-registered not-for-profit organisation. doi: 10.1002/cncr.21168, Dizon, D. S., Sabbatini, P. J., Aghajanian, C., Hensley, M. L., and Spriggs, D. R. (2002). Galateanu B, Pucau AI, Tircol SA, Tanase BC, Hudita A, Negrei C, Burcea-Dragomiroiu GT, Negreanu L, Vacaroiu IA, Ginghin O. Int J Mol Sci. and transmitted securely. Risk factors for these reactions included advanced disease, serous histological type, malignant ascites, and history of drug allergies. Wang, H. B., Shen, K., Yang, J. X., Huang, H. F., Li, Y., Wu, M., et al. The .gov means its official. All the statistical tests were two-tailed, and statistical significant level was defined as p-value < 0.05. also successfully developed a platinum desensitization protocol for patients with either a positive carboplatin skin test or a history of prior carboplatin hypersensitivity (Altwerger et al., 2017). Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. Anticancer. J. Clin. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2009) reported the successful re-treatment of the majority of patients with previous carboplatin-related hypersensitivity reactions. doi: 10.1016/S0140-6736(03)13718-X, Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., et al. We also collected survey data from cancer nurses on safety . Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. All accepted abstracts are available in theESMO 2017 Abstract Book. The PAGA project aims to adapt the ESMO Clinical Practice Guidelines by integrating Asian ethnic, scientific, socioeconomic, and local practice characteristics. 2017 Jul 1;28(suppl_4):iv100-iv118. (1994). The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. eCollection 2022. The cumulative incidence of severe carboplatin-related hypersensitivity was 1% after 15 cycles and 2% after 24 cycles, with a plateau beyond this cycle number, and 1% at >7,500 mg and 2% at >12,500 mg, with a plateau beyond this dose (Figures 1A,B ). Bayer to Highlight New Research at ESMO 2017 Congress - PR Newswire Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic ESMO Call to Action on COVID-19 Vaccinations and Patients with Cancer: Vaccinate. Allergy Asthma Proc (2011) 32(1):79.10.2500/aap.2011.32.3409 We found a higher incidence of carboplatin-related hypersensitivity among patients with advanced disease (stage IIIIV) with serous carcinoma and malignant ascites. European Hematology Association (EHA) and European . The term 'hypersensitivity' should be used to describe objectively reprodu- cible symptoms or signs initiated by exposure to a dened stimu- lus at a dose tolerated by normal persons. Life expectancy for cancer patients allergic and desensitized to carboplatin and non-allergic to, MeSH We also provide recommendations for the continuation of treatment in ovarian cancer patients. Paclitaxel plus platinum-based chemotherapy vs. conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Cardiopulmonary resuscitation and endotracheal intubation were performed, but the patient finally expired due to respiratory failure. (2009). The essential content of the guidelinesin condensed slide format in PDF or PowerPoint. In the majority of ovarian cancer cases, primary management entails surgical staging or cytoreduction, followed by systemic chemotherapy (Ledermann et al., 2013). Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations Front Immunol. II., Markman, M., Brown, J., et al. Management of infusion reactions to systemic anticancer therapy: ESMO Epub 2022 Nov 29. Background Hypersensitivity reactions (HSRs) are sometimes associated with the administration of certain cancer drugs. Summary format including algorithms, figures andtables for your presentations. Int. 105, 8183. This was the largest series of gynecological malignancies investigated for carboplatin-related hypersensitivity reactions. Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. Monitor. Recently, more and more patients with ovarian cancer have been receiving genetic counseling and testing, including BRCA1/2 and the other heterologous recombinant deficient (HRD) genes, because of the development of PAPP inhibitors. ESMO Clinical Practice Guidelines Provide your patients with the best care options Supporting your clinical decisions with ESMO's regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession. Emetogenicity of Chemotherapy : MASCC/ESMO Guidelines - EMJ 2012;97:217-33. doi: 10.1159/000335637. doi: 10.1200/JCO.2006.06.0913, Polyzos, A., Tsavaris, N., Kosmas, C., Arnaouti, T., Kalahanis, N., Tsigris, C., et al. Upon the occurrence of symptoms and signs, carboplatin infusion was immediately stopped. 2022 Mar 30;9(4):26. doi: 10.3390/medicines9040026. government site. Expert Perspectives: ESMO 2017 Changes Lung Cancer Practice Reducing the carboplatin infusion rate and employing desensitization protocols with anti-allergy medications are especially important for patients at high risk of carboplatin hypersensitivity to detect the hypersensitivity early and avoid severe hypersensitivity without compromising the efficacy of the antineoplastic regimen. 2011 Aug;12(8):806-14. doi: 10.1016/S1470-2045(10)70208-4. Such reactions could potentially be reduced or prevented by slowing the infusion rate and using a desensitization protocol involving anti-allergy medications. doi: 10.1016/j.ygyno.2006.04.002, Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., et al. We analyzed the relationships among the incidence, characteristics, risk factors, management, and outcomes of carboplatin-related hypersensitivity reactions in this patient population. Most IRs are mild with symptoms such as chills, fever, nausea, headache, skin rash, pruritus, etc. Rosell S, Blasco I, Garca Fabregat L, Cervantes A, Jordan K; ESMO Guidelines Committee. (1999). Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? The drug or food allergy in 735 patients receiving carboplatin-based chemotherapy. Necessary cookies enable core functionality. Clinical analysis of thirteen cases of hypersensitivity reactions to carboplatin. Analysis included treatment cycle, causative drug, severity of reaction as per CTCAE v4 . Europes Beating Cancer Plan in 60 minutes, World Cancer Report Updates Learning Platform, ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Recognition and Status of Medical Oncology, Status of Medical Oncology in Developing Countries, Shortages of Inexpensive, Essential Cancer Medicines, Accessibility and Availability of Medicines, Availability and Accessibility of Biomolecular Technologies in Oncology, CAREFOR, The Clinical Academic Cancer Research Forum, World Health Organization / United Nations, ESMO responses to European Union and Global Public Consultations, ESMO Facebook Roundtable: COVID-19 Vaccines and Cancer Care - The known, the unknown and the unknowable, ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, COVID-19 and cancer care in the ESMO journals. J. Gynecol. (2011). These risk factors can help identify patients at greater risk of developing hypersensitivity. Cancer Sci. Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. Please enable it to take advantage of the complete set of features! Accessibility Cancer 104, 640643. Incidence and intensity of anaphylaxis/hypersensitivity events: Table: 138P Discontinuations due to anaphylaxis/hypersensitivity were rare for PH IV (generally <1% except two TRYPHAENA arms: 1% and 3%); no discontinuations of PH FDC SC have been recorded so far. Oncol. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Univariate analysis for potential risk factors of carboplatin-related hypersensitivity reactions were assessed by the chi-square or Kruskal-Wallis test for categorical variables. Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. However, other studies have reported severe hypersensitivity reactions to cisplatin in patients with prior carboplatin hypersensitivity reactions (Zweizig et al., 1994; Dizon et al., 2002). Genc et al. These differences were likely related to the fact that patients with advanced disease, serous carcinoma, and ascetic malignant cells required significantly more carboplatin treatment cycles and higher carboplatin doses. NCT00567190, NCT02402712, NCT01358877, NCT00545688, NCT00976989, NCT02132949, NCT03493854, NCT03674112. doi: 10.1093/annonc/mdx216. Res. J. Gynecol. Monitor. Create your own personalised agenda and browse the complete scientific programme by day, topic, cancer type and track with the ESMO events app. Gerber, C. van den Hurk, P. Fernndez-Peas, D. Santini, F. Jahn, K. Jordan on behalf of the ESMO Guidelines Committee These ESMO Clinical Practice Guidelines provide recommendations on the . Up to 16% of patients with ovarian cancer who undergo treatment with carboplatin-containing regimens experience carboplatin-related hypersensitivity (Markman et al., 1999; Polyzos et al., 2001; Sliesoraitis and Chikhale, 2005). Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses. LUGANO-MADRID, 09 September, 2017 -The preliminary results of a study to be presented at the ESMO 2017 Congress in Madrid (1) show that socio-psychological factors have become more significant for . Evaluating whether any factors can predict carboplatin hypersensitivity, we identified a high correlation with the carboplatin cycle and cumulative dose (Pearson correlation coefficient 0.9318). Similarly, Kandel et al. The site is secure. Federal government websites often end in .gov or .mil. 24, 342351. Cancer. ESMO is a Swiss-registered not-for-profit organisation. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines (2017) 8 Pager Instructions Coverage Begins March 1, 2019 Coverage Ends: TBD 1. . Epub 2019 Jul 3. The independent sample t-test was used to evaluate how carboplatin cycle and dose correlated with the incidence of hypersensitivity and severe hypersensitivity reactions. Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. Overall, the evidence supports that the number of carboplatin cycles and dose are the principal risk factors for carboplatin-related hypersensitivity reactions, and that caution is warranted in cases of carboplatin infusion beyond 8 cycles or 3,500 mg. There was a striking difference in PFSmedian 16.8 versus 5.6 months, HR 0.52 (highly significant)with the difference in PFS sustained at 12- and 18-month landmarks. Carboplatin and pegylated liposomal doxorubicin (Pujade-Lauraine et al., 2010) or gemcitabine (Pfisterer et al., 2006) led to superior progression-free survival of patients with platinum-sensitive recurrent ovarian cancer compared to paclitaxel and carboplatin.